PVG Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

PVG Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,135	Closed	-$877K	–	97
2017 Q3	$877K	Buy	+10,135	New	+$813K	0.39%	56
2017 Q2	–	Sell	-12,785	Closed	-$887K	–	90
2017 Q1	$887K	Buy	+12,785	New	+$859K	0.27%	72

Other funds holding XBI

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PVG Asset Management's XBI Position: Q4 2017 in Review

PVG Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2017, closing a stake of 10,135 shares — an estimated $877K sold.

PVG Asset Management first reported a position in XBI in Q1 2017 and held it in 2 quarters. The position peaked at $887K in Q1 2017. 397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

PVG Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2017 after selling out during the quarter.
PVG Asset Management sold 10,135 State Street SPDR S&P Biotech ETF shares in Q4 2017, an estimated $877K.
PVG Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 2 quarters.
PVG Asset Management's State Street SPDR S&P Biotech ETF position peaked at $887K in Q1 2017.
397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on PVG Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.